Further brain tumor trials are planned in which vorinostat will be combined with other drugs. Including vorinostat in treatment of advanced non-small-cell lung carcinoma (NSCLC) showed improved response rates and increased median progression free survival and overall survival.It has given encouraging results in a phase II trial for myelodysplastic syndromes in combination with idarubicin and cytarabine. Preclinical investigations
Vorinostat is being investigated as a potential HIV latency reversing agent (LRA) as part of an investigational therapeutic strategy known as "shock and kill." Vorinostat was shown to reactivate HIV in latently HIV-infected T cells, both in vitro and in vivo.Vorinostat also has shown some activity against the pathophysiological changes in α1-antitrypsin deficiency and cystic fibrosis. Recent evidence also suggests vorinostat can be a therapeutic tool for Niemann-Pick type C1 (NPC1), a rare lysosomal lipid storage disease.Preclinical experiments by University of Alabama at Birmingham researchers suggest the cancer drugs vorinostat, belinostat and panobinostat might be repurposed to treat infections caused by human papillomavirus, or HPV. See also
Trichostatin A

References
External links
Vorinostat bound to proteins in the PDB
Radiation therapyAll current treatments have had varying degrees of success. The vinca alkaloids and anthracyclines have been used most commonly in ECD treatment. Prognosis
Erdheim–Chester disease was previously associated with high mortality rates. In 2005, the survival rate was below 50% at three years from diagnosis. More recent reports of patients treated with Interferon therapy describe an overall 5-year survival of 68%. Long-term survival is currently even more promising, although this impression is not reflected in the recent literature. More recent studies have reported that patients receiving targeted therapies showed no disease progression. It was concluded that targeted therapies (BRAF and/or MEK inhibitors) were dramatically efficacious. Epidemiology
Approximately 500 cases have been reported in the literature to date. ECD affects predominantly adults, with a mean age of 53 years. History
The first case of ECD was reported by the American pathologist William Chester in 1930, during his visit to the Austrian pathologist Jakob Erdheim in Vienna. Society and culture
The Erdheim–Chester Disease Global Alliance is a support and advocacy group with the goal of raising awareness of and promoting research into ECD. ECD families and patients are also supported by the Histiocytosis Association, Inc.

Media
In the TV show House, season 2 episode 17, "All In", the final diagnosis of a 6-year-old boy who presents with bloody diarrhea and ataxia is Erdheim–Chester disease. References
Further reading
External links
01067 at CHORUS